A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT ID: NCT03271021

Last Updated: 2022-01-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1488 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-17

Study Completion Date

2018-09-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy over 12 weeks of FMX101 topical foam containing 4% minocycline compared to vehicle in the treatment of subjects with moderate-to-severe facial acne vulgaris. Qualified subjects will be randomized to receive 1 of the following 2 treatments:

* FMX101 4% minocycline foam
* Vehicle foam

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FMX101, 4% minocycline foam

FMX101, 4% minocycline foam applied topically once daily for 12 weeks

Group Type EXPERIMENTAL

FMX101

Intervention Type DRUG

FMX101, 4% minocycline foam

Vehicle foam

Vehicle foam applied topically once daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Vehicle Foam

Intervention Type DRUG

Vehicle Foam

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FMX101

FMX101, 4% minocycline foam

Intervention Type DRUG

Vehicle Foam

Vehicle Foam

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has facial acne vulgaris with:

1. 20 to 50 inflammatory lesions (papules, pustules, and nodules)
2. 25 to 100 non-inflammatory lesions (open and closed comedones)
3. No more than 2 nodules on the face
4. IGA score of moderate (3) to severe (4)
2. Willing to use only the supplied non-medicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study.

Exclusion Criteria

1. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations.
2. Sunburn on the face.
Minimum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vyne Therapeutics Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Foamix Investigational Site #376

Phoenix, Arizona, United States

Site Status

Foamix Investigational Site #395

Tucson, Arizona, United States

Site Status

Foamix Investigational Site #315

Bryant, Arkansas, United States

Site Status

Foamix Investigational Site #340

Fort Smith, Arkansas, United States

Site Status

Foamix Investigational SIte #377

Little Rock, Arkansas, United States

Site Status

Foamix Investigational Site #366

Encino, California, United States

Site Status

Foamix Investigational Site #403

Los Angeles, California, United States

Site Status

Foamix Investigational Site #303

Murrieta, California, United States

Site Status

Foamix Investigational Site #369

Northridge, California, United States

Site Status

Foamix Investigational Site #387

Palm Springs, California, United States

Site Status

Foamix Investigational Site #393

Pasadena, California, United States

Site Status

Foamix Investigational Site #380

Poway, California, United States

Site Status

Foamix Investigational Site # 328

Sacramento, California, United States

Site Status

Foamix Investigational Site #313

San Diego, California, United States

Site Status

Foamix Investigational Site #336

San Luis Obispo, California, United States

Site Status

Foamix Investigational Site #309

Santa Ana, California, United States

Site Status

Foamix Investigational Site #325

Santa Monica, California, United States

Site Status

Foamix Investigational Site #375

Temecula, California, United States

Site Status

Foamix Investigational Site #381

Aventura, Florida, United States

Site Status

Foamix Investigational SIte #371

Boca Raton, Florida, United States

Site Status

Foamix Investigational Site #311

Boca Raton, Florida, United States

Site Status

Foamix Investigational Site #398

Brandon, Florida, United States

Site Status

Foamix Investigational Site #329

Clearwater, Florida, United States

Site Status

Foamix Investigational Site #378

Davie, Florida, United States

Site Status

Foamix Investigational Site #396

DeLand, Florida, United States

Site Status

Foamix Investigational Site #392

Doral, Florida, United States

Site Status

Foamix Investigational Site #318

Fort Myers, Florida, United States

Site Status

Foamix Investigational Site #401

Hialeah, Florida, United States

Site Status

Foamix Investigational Site #400

Hialeah, Florida, United States

Site Status

Foamix Investigational Site #383

Lake Worth, Florida, United States

Site Status

Foamix Investigational Site #397

Miami, Florida, United States

Site Status

Foamix Investigational Site #370

Miami, Florida, United States

Site Status

Foamix Investigational Site #346

Miami Lakes, Florida, United States

Site Status

Foamix Investigational Site #347

Miami Lakes, Florida, United States

Site Status

Foamix Investigational Site #306

North Miami Beach, Florida, United States

Site Status

Foamix Investigational Site #312

Ormond Beach, Florida, United States

Site Status

Foamix Investigational Site #362

South Miami, Florida, United States

Site Status

Foamix Investigational SIte #382

Tamarac, Florida, United States

Site Status

Foamix Investigational Site #399

Tampa, Florida, United States

Site Status

Foamix Investigational Site #385

Tampa, Florida, United States

Site Status

Foamix Investigational Site #394

Tampa, Florida, United States

Site Status

Foamix Investigational Site #360

West Palm Beach, Florida, United States

Site Status

Foamix Investigational Site #368

Columbus, Georgia, United States

Site Status

Foamix Investigational Site #336

Sandy Springs, Georgia, United States

Site Status

Foamix Investigational Site #384

Nampa, Idaho, United States

Site Status

Foamix Investigational Site #345

Skokie, Illinois, United States

Site Status

Foamix Investigational Site #390

West Dundee, Illinois, United States

Site Status

Foamix Investigational Site #365

Indianapolis, Indiana, United States

Site Status

Foamix Investigational Site #316

New Albany, Indiana, United States

Site Status

Foamix Investigational Site #361

Plainfield, Indiana, United States

Site Status

Foamix Investigational Site #331

South Bend, Indiana, United States

Site Status

Foamix Investigational Site #320

Louisville, Kentucky, United States

Site Status

Foamix Investigational SIte #367

Louisville, Kentucky, United States

Site Status

Foamix Investigational Site #317

New Orleans, Louisiana, United States

Site Status

Foamix Investigational SIte #373

New Orleans, Louisiana, United States

Site Status

Foamix Investigational Site #388

Glenn Dale, Maryland, United States

Site Status

Foamix Investigational Site #304

Beverly, Massachusetts, United States

Site Status

Foamix Investigational Site #314

Brighton, Massachusetts, United States

Site Status

Foamix Investigational Site #334

Watertown, Massachusetts, United States

Site Status

Foamix Investigational Site #322

Saint Joseph, Missouri, United States

Site Status

Foamix Investigational Site #372

St Louis, Missouri, United States

Site Status

Foamix Investigational Site #391

Lincoln, Nebraska, United States

Site Status

Foamix Investigational Site # 327

Omaha, Nebraska, United States

Site Status

Foamix Investigational Site #332

Las Vegas, Nevada, United States

Site Status

Foamix Investigational Site #344

Portsmouth, New Hampshire, United States

Site Status

Foamix Investigational Site #356

Berlin, New Jersey, United States

Site Status

Foamix Investigational Site #337

Verona, New Jersey, United States

Site Status

Foamix Investigational Site #321

Charlotte, New York, United States

Site Status

Foamix Investigational Site #355

New York, New York, United States

Site Status

Foamix Investigational Site #363

New York, New York, United States

Site Status

Foamix Investigational Site #307

Stony Brook, New York, United States

Site Status

Foamix Investigational Site #350

Charlotte, North Carolina, United States

Site Status

Foamix Investigational Site #348

Winston-Salem, North Carolina, United States

Site Status

Foamix Investigational Site #364

Fargo, North Dakota, United States

Site Status

Foamix Investigational Site #310

Bexley, Ohio, United States

Site Status

Foamix Investigational Site #386

Cincinnati, Ohio, United States

Site Status

Foamix Investigational Site #353

Cleveland, Ohio, United States

Site Status

Foamix Investigational Site #330

Dublin, Ohio, United States

Site Status

Foamix Investigational Site #302

Norman, Oklahoma, United States

Site Status

Foamix Investigational Site #335

Exton, Pennsylvania, United States

Site Status

Foamix Investigational Site #349

Hershey, Pennsylvania, United States

Site Status

Foamix Investigational Site #323

Jenkintown, Pennsylvania, United States

Site Status

Foamix Investigational Site #319

Charleston, South Carolina, United States

Site Status

Foamix Investigational Site #305

Mt. Pleasant, South Carolina, United States

Site Status

Foamix Investigational Site #308

Knoxville, Tennessee, United States

Site Status

Foamix Research Site # 301

Arlington, Texas, United States

Site Status

Foamix Investigational Site #374

Arlington, Texas, United States

Site Status

Foamix Investigational SIte #341

Austin, Texas, United States

Site Status

Foamix Investigational Site #351

Austin, Texas, United States

Site Status

Foamix Investigational Site #402

Bryan, Texas, United States

Site Status

Foamix Investigational Site #358

Dallas, Texas, United States

Site Status

Foamix Investigational Site #333

Houston, Texas, United States

Site Status

Foamix Investigational Site #352

Houston, Texas, United States

Site Status

Foamix Investigational Site # 324

Pflugerville, Texas, United States

Site Status

Foamix Investigational SIte #379

Lynchburg, Virginia, United States

Site Status

Foamix Investigational Site #343

Norfolk, Virginia, United States

Site Status

Foamix Investigational Site #389

Seattle, Washington, United States

Site Status

Foamix Investigational Site #359

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FX2017-22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.